Kristian Werling said that 2017 was “a very interesting year for life science dealmaking. There was an absence of the so-called mega-deals that we’ve seen in a few recent years … But there were a number of deals in the middle market – in the billion and a half to two billion dollars range – so overall it was a really productive year for companies looking to build the product pipeline.”